Literature DB >> 8100296

Towards improved thrombolytic therapy.

D Collen1.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8100296     DOI： 10.1016/0140-6736(93)91888-s

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Thrombolytic Therapy: The Treatment of Choice in Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.

Authors:  J F Liang; Y T Li; M E Connell; V C Yang
Journal:  AAPS PharmSci       Date:  2000

Review 3.  Hirudin and excess bleeding. Implications for future use.

Authors:  U Zeymer; K L Neuhaus
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

4.  Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease.

Authors:  O D Pedersen; J Gram; J Jespersen
Journal:  Heart       Date:  1997-02       Impact factor: 5.994

5.  Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.

Authors:  Bi-Sen Ding; Claudia Gottstein; Andrea Grunow; Alice Kuo; Kumkum Ganguly; Steven M Albelda; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

6.  Expression of a novel chimeric truncated t-PA in CHO cells based on in silico experiments.

Authors:  Fatemeh Davami; Soroush Sardari; Keivan Majidzadeh-A; Mehdi Hemayatkar; Farzaneh Barkhrdari; Maryam Omidi; Mehrnaz Azami; Ahmad Adeli; Noushin Davoudi; Fereidoun Mahboudi
Journal:  J Biomed Biotechnol       Date:  2010-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.